Paper Details

  1. Home
  2. Paper Details

Pharmacokinetics of pyrazinamide in children with primary progressive disease of lungs.

Author: AryaD S, NandaveM, OjhaS K, SemwalO P

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study explored the pharmacokinetics of pyrazinamide (PZA) in children with primary progressive pulmonary disease using HPLC, as the recommended dosages for children are often extrapolated from adult studies and may not be accurate.
Paper Details　
Original Abstract of the Article :
As the dosages recommended for children are based on weight, empirical and derived by extrapolation from the studies in adults, pyrazinamide (PZA) pharmacokinetics in children is likely to be different from adults. Limited information exists regarding the pharmacokinetics of PZA in paediatric patien...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/19179681

データ提供：米国国立医学図書館（NLM）

Pyrazinamide in Children: Navigating a Complex Terrain

This research takes us on a journey through the complex world of pyrazinamide (PZA), a medication used to treat tuberculosis, and its pharmacokinetics in children with primary progressive disease (PPD) of the lungs. Imagine a desert landscape, where a child is struggling with a serious lung infection. Understanding the pharmacokinetics of PZA in children is crucial for optimizing treatment and ensuring a successful outcome.

Optimizing Treatment for Children

The study explores the pharmacokinetic profile of PZA in children with PPD of the lungs, highlighting the differences between children and adults. This research, like a skilled desert guide, provides valuable insights into the optimal dosing and monitoring of PZA in children, ensuring they receive the right amount of medication for their specific needs.

Ensuring Effective Treatment

This study emphasizes the importance of tailoring treatment to the unique needs of children with PPD of the lungs. Just as a desert nomad carefully navigates the landscape to find the best route, healthcare professionals must carefully consider the unique pharmacokinetic profile of PZA in children to ensure effective treatment and a favorable outcome.

Dr. Camel's Conclusion

This study underscores the importance of understanding the pharmacokinetics of pyrazinamide in children with primary progressive disease of the lungs. By tailoring treatment to individual needs, we can ensure effective therapy and improve the chances of a successful outcome for these children. Just as a wise desert nomad adapts their journey to the terrain, healthcare professionals must be vigilant in optimizing treatment for children with PPD of the lungs.

Date :
  1. Date Completed 2009-04-01
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

19179681

DOI: Digital Object Identifier

19179681

Related Literature

Article Analysis
・Side Effects of pyrazinamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.